Skip to main content

Qiagen Reports Increased Q2 Revenue, Profit ...

NEW YORK, Aug. 8 (GenomeWeb News) - Qiagen reported today a slight rise in second-quarter sales and a jump in profit.

 

The company reported second-quarter sales of $100.4 million, versus $98.6 million a year earlier. Excluding $9.9 million of net sales related to the sale of its synthetic DNA business unit in the second quarter of 2004, consolidated net sales increased 13 percent from $88.7 million in 2004.

R&D costs for the period increased to $9.4 million from $9.3 million year over year.

 

Qiagen's net income for the quarter climbed 57 percent to $13.8 million, or $.09 per share, compared with $8.8 million, or $.06 per share, in the year-ago quarter.

Qiagen said it had around $157 million cash and equivalents, and $51.8 million in marketable securities as of June 30.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.